References
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277–300.
- U.S. Cancer Statistics Working Group. United States cancer statistics: 1999–2007 incidence and mortality web-based report. 2010; Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute.
- Kunkel EJ, Bakker JR, Myers RE, Oyesanmi O, Gomella LG. Biopsychosocial aspects of prostate cancer. Psychosomatics. 2000; 41: 85–94.
- Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, etal. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol. 2011; 18: 5875–83. [PubMed Abstract].
- National Cancer Institute. Facing forward: life after cancer treatment. 2012. [cited 2014 Jan 22]. Available from: https://pubs.cancer.gov/ncipl/detail.aspx?prodid = P119#.
- Institute of Medicine. From cancer patient to cancer survivor: lost in transition. 2005; National Academies Press. [cited 2014 Jan 22]. Available from: http://www.nap.edu/catalog.php?record_id = 11468.
- American Cancer Society. Survivorship: during and after treatment. 2014. [cited 2014 Jan 22]. Available from: http://www.cancer.org/treatment/survivorshipduringandaftertreatment/index?sitearea =.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42: 377–81.
- National Comprehensive Cancer Network. NCCN guidelines. [cited 2013 Aug 2]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
- Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, etal. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368: 436–45.
- Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, etal. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250–61.
- Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, etal. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006; 24: 3979–83.
- D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, etal. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25: 2420–5.
- Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352: 154–64.
- Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294: 238–44.